🇺🇸 FDA
Patent

US 10369232

Allele selective gene editing and uses thereof

granted A61KA61K48/005A61P

Quick answer

US patent 10369232 (Allele selective gene editing and uses thereof) held by ARCTURUS THERAPEUTICS, INC. expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ARCTURUS THERAPEUTICS, INC.
Grant date
Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K48/005, A61P, A61P15/00, A61P17/00